Corvus Pharmaceuticals Inc.
CRVS | NASDAQ
$13.10
+$0.68 (+5.48%)
Sep 22, 2026, 12:51 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -40.53 | -5.25 | -3.13 | -0.96 | -2.34 | -17.80 |
PEG Ratio | 0.50 | -0.06 | 0.09 | 0.07 | -0.01 | 0.21 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 9.93 | 10.02 | 2.18 | 0.71 | 1.04 | 1.45 |
P/FCF Ratio | -18.44 | -12.83 | -3.53 | -1.45 | -2.75 | -3.01 |
P/OCF Ratio | -18.54 | -12.83 | -3.53 | -1.46 | -2.75 | -3.02 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.02 | 0.03 | 0.04 | 0.05 | 0.04 | 0.03 |
Quick Ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 | 3.73 |
Current Ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 | 3.73 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | -2.58K | -81.04 |
Return on Equity | -24.97% | -191.27% | -69.87% | -73.61% | -44.50% | -8.31% |
Return on Assets | -21.49% | -90.40% | -59.34% | -60.53% | -39.51% | -7.01% |
Return on Invested Capital | -69.15% | -81.77% | -58.43% | -55.46% | -38.32% | -58.77% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove CRVS